Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Boehringer Said to Consider Nixing Allowances for Some Wholesalers, Denies Intention to Narrow Distributors
July 23, 2019
- Lonasen Effective in Adolescent Japanese Schizophrenia Patients: Sumitomo Dainippon
July 23, 2019
- Nichi-Iko Gets Distribution Rights to Chugai’s Ulcerlmin
July 23, 2019
- Shire’s Vonvendi Filed in Japan
July 23, 2019
- Aspen Japan to Take Over Bristol’s Antiarrhythmic Agent
July 23, 2019
- Ono/BMS, Bayer to Develop Opdivo-Stivarga Combo
July 22, 2019
- Sumitomo Dainippon Offers to Buy Cynata
July 22, 2019
- Nitto Pharma Accelerating Development of Gut Bacteria Drugs, Eyes Clinical Studies within 3 Years
July 22, 2019
- Tarlige Most Pitched Drug in April: Impact Track Survey
July 19, 2019
- BACE Inhibitor Elenbecestat Shows No Major Effect on Synaptic Function in Nonclinical Study: Eisai
July 19, 2019
- IPO Pending, StemRIM Looks to File World’s 1st Regeneration-Inducing Med Next Year: CEO
July 18, 2019
- Astellas Hitches Frequency’s Regenerative Hearing Loss Therapy Outside US
July 18, 2019
- Astellas/Seattle Genetics’ ADC Filed in US for Urothelial Cancer
July 18, 2019
- Halaven Bags China Approval for Breast Cancer: Eisai
July 18, 2019
- Ono’s Yamaguchi Plant Completed, Set to Go Live Next Spring
July 18, 2019
- Alexion Promotes Kimihiro Kasamo to Japan Chief
July 18, 2019
- Bayer Flatly Denies Its Employee’s Allegations in 2nd Oral Proceedings for Damage Suit
July 18, 2019
- Takeda Gears Up for Clinical Testing of 1st iPS-Derived CAR-T, Eyes Trial Launch in 2021
July 17, 2019
- Takeda Launches New Manufacturing Facility for Ninlaro at Irish Plant
July 17, 2019
- JT’s HIF-PH Inhibitor Enarodustat Non-Inferior to Nesp
July 16, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…